Pentoxifylline inhibits PDGF-induced proliferation of and TGF-β-stimulated collagen synthesis by vascular smooth muscle cells

Journal of Molecular and Cellular Cardiology

Volumn 31, Issue 4, 1999, Pages 773-783

  Chen, Yung Ming ^a   Wu, Kwan Dun ^a   Tsai, Tun Jun ^a   Hsieh, Bor Shen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Collagen; Pentoxifylline; Proliferation; Vascular smooth muscle cell

Indexed keywords

ANTIMITOTIC AGENT; BUCLADESINE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC GMP; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NONAPEPTIDE; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; MALE; MITOSIS INHIBITION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RADIOASSAY; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALIA;

EID: 0033119248     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1998.0910     Document Type: Article

References (40)

1. AMENTO EP, EHSANI N, PALMER H, LIBBY P, 1991. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle ells. Atherosclerosis Throm 11: 1223-1230.
2. BALDIN V, LUKAS J, MARCOTE MJ, PAGANO M, DRAETTA G, 1993. Cyclin D1 is a protein required for cell cycle progression in G1. Gene Develop 7: 812-821.
3. BELLOC F, JALOUSTRE C, DUMAIN P, LACOMBE F, LENOBLE M, BOISSEAU MR, 1995. Effect of pentoxifylline on apoptosis of cultured cells. J Carviovasc Pharmacol 25 (Suppl. 2): S71-S74.
4. BERMAN B, MATTHEW R, DUNCAN MR, 1989. Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity. J Invest Dermatol 92: 605-610.
5. CHAO T-SO, BYRON KL, LEE K-M, VILLEREAL M, ROSNER MR, 1992. Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor. J Biol Chem 267: 19876-19883.
6. CHIJIWA T, MISHIMA A, HAGIWARA M, SANO M, HAYASHI K, INOUE T, NAITO K, TOSHIOKA T, HIDAKA H, 1990. Inhibitor of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-bromocinnamyl (amino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma. J Biol Chem 265: 5267-5272.
7. CLOWES AW, REIDY MA, CLOWES MM, 1983. Mechanisms of stenosis after arterial injury. Lab Invest 49: 208-215.
8. DUNCAN MR, HASAN A, BERMAN B, 1995. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol 104: 282-286.
9. EICHHOLTZ T, DE BONT DBA, DE WIDT J, LISKAMP RMJ, PLOEGH HL, 1993. A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem 289: 1982-1986.
10. FERNS GAA, RAINES EW, SPRUGEL KH, MOTANI AS, REIDY MA, ROSS R, 1991. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253: 1129-1132.
11. GILLINGS DB, 1995. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol 25 [Suppl 2]: S44-S50.
12. GLASS DB, CHEN H-C, MENDE-MUELLER L, REED J, WALSH DA, 1989. Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J Biol Chem 264: 8802-8810.
13. GOLDEN MA, AU YPT, KIRKMAN TR, WILCOX JN, RAINES EW, ROSS R, CLOWES AW, 1991. Platelet-derived growth factor activity and mRNA expression in healing vascular grafts in baboons. Association in vivo of platelet-derived growth factor mRNA and protein with cellular proliferation. J Clin Invest 87: 406-414.
14. GRAVES LM, BORNFELDT KE, RAINES EW, POTTS BC, MACDONALD SG, ROSS R, KREBS EG, 1993. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 90: 10300-10304.
15. HICHAMI A, BIOCHOT E, GERMAIN N, COQUERET O, LAGENTE V, 1996. Interactions between cAMP-and cGMP-dependent protein kinase inhibitors and phosphodiesterase IV inhibitors on arachidonate release from human monocytes. Life Sci 59: 255-261.
16. HINZE JH, GRIGOLEIT HG, RETHY B, 1976. Bioavailability and pharmacokinetics of pentoxifylline and Trental 400 in man. Pharmatherapeutica 1: 160-171.
17. ISBRUCKER RA, PETERSON TC, 1998. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol Appl Pharmacol 149: 120-126.
18. JACKSON CL, SCHWARTZ SM, 1992. Pharmacology of smooth muscle cell replication. Hypertension 20: 713-736.
19. JACKSON CL, RAINES EW, ROSS R, REIDY MA, 1993. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arteriosclerosis Throm 13: 1218-1226.
20. KINDY MS, CHANG C-J, SONENSHEIN GE, 1988. Serum deprivation of vascular smooth muscle cells enhances collagen gene expression. J Biol Chem 263: 11426-11430.
21. L'ALLEMAIN G, LAVOIE JN, RIVARD N, BALDIN V, POUYSSEGUR J, 1997. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in flbroblasts. Oncogene 14: 1981-1990.
22. MAJESKY MW, REIDY MA, BROWN-POPE DF, HART CE, WILCOX JN, SCHWARTZ SM, 1990. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 111: 2149-2158.
23. MAJESKY MW, LINDNER V, TWARDZIK DR, SCHWARTZ SM, REIDY MA, 1991. Production of transformin growth factor β1 during repair of arterial injury. J Clin Invest 88: 904-910.
24. MATOUSOVICK, GRANDE JP, CHINI CCS, CHINI EN, DOUSA TP, 1995. Inhibition of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 96: 401-410.
25. MCKENZIE FR, POUYSSEGUR J, 1996. cAMP-mediated growth inhibition in flbroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition. J Biol Chem 271: 13476-13483.
26. NIKOL S, ISNER JM, PICKERING JG, KEARNEY M, LECLERC G, WEIR L, 1992. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions. J Clin Invest 90: 1582-1592.
27. OKADA Y, KATSUDA S, WATANABE H, NAKANISHI I, 1993. Collagen synthesis of human arterial smooth muscle cells: effects of platelet-derived growth factor, transforming growth factor-β1 and interleukin-1. Acta Pathologica Japonica 43: 160-167.
28. PAN X, ARSUZ E, KRZANOWSKI JJ, FITZPATRICK DF, POLSON JB, 1994. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 48: 827-835.
29. PETERSON TC, ISBRUCKER RA, HOOPER ML, 1994. In vitro effect of platelet-derived growth factor on fibro-proliferation and effect of cytokine antagonists. Immunopharmacol 28: 259-270.
30. PIETILA K, NIKKARI T, 1983. Role of arterial smooth muscle cell in the pathogenesis of atherosclerosis. Med Biol 61: 31-44.
31. PINZANI M, MARRA F, CALIGIURI A, DEFRANCO R, GENTILINI A, FAILLI P, GENTILINI P, 1996. Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br J Pharmacol 199: 1117-1114.
32. PREAUX A-M, MALLAT A, ROSENBAUM J, ZAFRANI E-S, MAVIER P, 1997. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 26: 315-322.
33. RITZENTHALER JD, GOLDSTEIN RH, FINE A, SMITH BD, 1993. Regulation of the α1(I) collagen promoter via transforming growth factor-beta activation element. J Biol Chem 268: 13625-13631.
34. ROSS R, 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809.
35. TSAI T-J, LIN R-H, CHANG C-C, CHEN Y-M, CHEN C-F, KO F-N, TENG C-M, 1995. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 70: 91-99.
36. TSUBOI Y, SHANKLAND SJ, GRANDE JP, WALKER HJ, JOHNSON RJ, DOUSA TP, 1996. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 98: 262-270.
37. WARD A, CLISSOLD SP, 1987. Pentoxifylline, a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97.
38. WOLF YG, RASMUSSEN LM, RUOSLAHTI, 1994. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 93: 1172-1178.
39. YANG KD, CHUEN H-L, SHAIO M-F, 1995. Pentoxifylline augments but does not antagonize TNFα-mediated neuroblastoma cell differentiation: modulation of calcium mobilization but not cAMP. Biochem Biophys Res Commun 211: 1006-1014.
40. YOSHIDA Y, MITSUMATA M, LING G, JIANG J, SHU Q, 1997. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 811: 459-470.